Volume 8.07 | Feb 25

Mammary Cell News 8.07 February 25, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
 
TOP STORY
Researchers Develop a Novel Cancer Treatment Approach Based on Evolutionary Principals to Inhibit Chemo-Resistance, Prolong Progression-Free Survival
Researchers report that adaptive therapy is effective in preclinical mouse models of triple-negative and ER+ breast cancer. They treated mice with the common breast cancer chemotherapeutic agent paclitaxel according to three different treatment strategies in which the dose of paclitaxel is the same but doses are skipped when the tumor responds to therapy. [Press release from Moffitt Cancer Center discussing online prepublication in Science Translational Medicine] Press Release | Full Article
Culture and Characterize Human Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Human) Free Protocols
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Effect of Actin Organization on the Stiffness of Living Breast Cancer Cells Revealed by Peak-Force Modulation Atomic Force Microscopy
Researchers studied the correlation between cytoskeleton organization and stiffness of three epithelial breast cancer cells lines with different degree of malignancy: MCF-10A (healthy), MCF-7 (tumorigenic/non-invasive) and MDA-MB-231 (tumorigenic/invasive). [ACS Nano] Abstract

TOM1L1 Drives Membrane Delivery of MT1-MMP to Promote ERBB2-Induced Breast Cancer Cell Invasion
Investigators demonstrated that TOM1L1 upregulation enhances the invasiveness of ERBB2-transformed cells. This pro-tumoral function did not involve SRC, but implicated membrane-bound membrane-type 1 MMP (MT1-MMP)-dependent activation of invadopodia, membrane protrusions specialized in extracellular matrix degradation. [Nat Commun] Full Article

In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors
Researchers established an in vivo approach to track the fate of tumor cells based on a novel epithelial-to-mesenchymal transition-driven fluorescent color switching breast cancer mouse model and intravital two-photon laser scanning microscopy. [Cancer Res] Abstract

Mitochondrial Reprogramming Regulates Breast Cancer Progression
Scientists characterized the critical components regulating mitochondrial function in breast tumorigenesis. Experiments were conducted to assess the potential of these molecules for exosome based biomarker development. [Clin Cancer Res] Abstract

Therapeutic siRNA for Drug-resistant HER2-Positive Breast Cancer
The authors systematically identified an optimal HER2 siRNA from 76 potential sequences and demonstrated its utility in overcoming intrinsic and acquired resistance to trastuzumab and lapatinib in 18 HER2-positive cancer cell lines. [Oncotarget] Full Article

Suicide Gene-Engineered Stromal Cells Reveal a Dynamic Regulation of Cancer Metastasis
Researchers observed that the selective apoptosis of cancer-associated fibroblasts at early timepoints did not affect primary tumor growth, but instead increased the presence of tumor-associated macrophages and the metastatic spread of breast cancer cells to the lung and bone. [Sci Rep] Full Article | Press Release 

Glucose Is a Key Driver for GLUT1-Mediated Nanoparticles Internalization in Breast Cancer Cells
The authors demonstrated that the uptake of glucose-coated magnetic nanoparticles (MNPs) by mesenchymal-like cells remains constant when the glucose in the medium is increased from low to high concentration, while the MNPs uptake by epithelial-like cells is significantly reduced. [Sci Rep] Full Article

Interferon-Induced Transmembrane Protein 1 (IFITM1) Overexpression Enhances the Aggressive Phenotype of SUM149 Inflammatory Breast Cancer Cells in a Signal Transducer and Activator of Transcription 2 (STAT2)-Dependent Manner
Scientists found that IFITM1 was constitutively overexpressed at the mRNA and protein levels in triple-negative SUM149 inflammatory breast cancer (IBC) cells, but that it was not expressed in SUM190 and MDA-IBC-3 IBC cells, and that suppression of IFITM1 or blockade of the IFNα signaling pathway significantly reduced the aggressive phenotype of SUM149 cells. [Breast Cancer Res] Full Article

CXCR4-SDF-1 Interaction Potentially Mediates Trafficking of Circulating Tumor Cells in Primary Breast Cancer
Investigators aimed to assess correlation between CTCs and plasma cytokines in primary breast cancer (PBC) patients.The study included 147 chemotherapy naïve PBC patients. [BMC Cancer] Full Article

CLINICAL RESEARCH

Phase II Study on the Efficacy and Safety of Lapatinib Administered Beyond Disease Progression and Combined with Vinorelbine in HER-2/neu- Positive Advanced Breast Cancer: Results of the CECOG LaVie Trial
Researchers evaluated the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-kinase inhibitor, as late-line regimen administered beyond previous disease progression on prior lapatinib in patients with HER-2/neu- positive metastatic breast cancer. [BMC Cancer] Full Article

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
REVIEWS
Lipid-Sensors, Enigmatic-Orphan and Orphan Nuclear Receptors as Therapeutic Targets in Breast-Cancer
The authors provide an overview of the literature available on the expression and potential role played by lipid-sensors, enigmatic-orphans and orphan-receptors in breast-cancer. The data are complemented by an analysis of the expression levels of each selected nuclear-receptor in the PAM50 breast-cancer groups, following re-elaboration of the data publicly available. [Oncotarget] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
Pfizer Receives Expanded FDA Approval for IBRANCE (Palbociclib) in HR+, HER2 Metastatic Breast Cancer
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HR2) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy. [Pfizer Inc.] Press Release

NCCN, in Collaboration with Pfizer, Awards Ten Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program, in collaboration with Pfizer Independent Grants for Learning & Change, has awarded ten grants for project proposals to develop and adopt evidence-based initiatives to improve patient care and outcomes in metastatic breast cancer. [The National Comprehensive Cancer Network®] Press Release

Cutting Edge Medical Research Ideas Receive £23.2 Million Boost
The Medical Research Council is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients. [Medical Research Council] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW AACR Annual Meeting 2016
April 16-20, 2016
New Orleans, United States

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellowship – Breast and Prostate Cancer Molecular Mechanisms (Feinberg School of Medicine)

NEW Postdoctoral Fellowship – Epigenetic Reprogramming of Breast Cancer Stem Cells (University of Toronto)

Postdoctoral Fellowship – Various Projects in Cancer Biology (National University of Singapore)

Postdoctoral Fellowship – Genetic and Epigenetic Variability in Breast Cancer (The University of Tennessee Health Science Center)

Clinical Research Fellow – Breast Pathology (Institute of Cancer Research)

Lead Bioinformatician – Breast Cancer Research (Institute of Cancer Research)

Pathologist – Breast/Gastrointestinal/Genitourinary Cancer (Beth Israel Deaconess Medical Center)

Postdoctoral Fellowships – Breast and Prostate Cancer (Baylor College of Medicine)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Biology (Washington University School of Medicine)

Professorship – Clinical Breast Cancer Research (University of Leeds)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Development (University of Pennsylvania)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us